$FHLD
Freedom Holdings, Inc.

2024 Q2 Form 10-Q Financial Statement

#000147793224002996 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.00 $72.00
YoY Change -98.26% -96.95%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $265.6K $14.57K
YoY Change -24.87% -48.96%
Operating Profit -$265.6K -$14.57K
YoY Change -24.87% -48.96%
Interest Expense $2.863K $2.863K
YoY Change -2.35% -2.82%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$234.4K -$17.44K
YoY Change -34.23% -44.64%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 55.31M shares 55.31M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $2.184K $21.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.184K $21.00
YoY Change 642.86% -99.72%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $2.184K $21.00
Total Long-Term Assets $0.00 $0.00
Total Assets $2.184K $21.00
YoY Change 642.86% -99.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $22.90K $47.66K
YoY Change -52.97% -18.79%
Accrued Expenses $240.0K $240.0K
YoY Change -0.68% -0.92%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $272.8K $304.7K
YoY Change -16.56% -9.76%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $272.8K $304.7K
Total Long-Term Liabilities
Total Liabilities $395.2K $431.1K
YoY Change -4.75% 1.07%
SHAREHOLDERS EQUITY
Retained Earnings -$10.43M -$10.20M
YoY Change 2.58% 3.91%
Common Stock $5.841K $5.631K
YoY Change 5.6% 14.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$393.0K -$431.1K
YoY Change
Total Liabilities & Shareholders Equity $2.184K $21.00
YoY Change 642.86% -99.72%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$234.4K -$17.44K
YoY Change -34.23% -44.64%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We maintain our cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. We continually monitor our banking relationships and consequently have not experienced any losses in our accounts. We believe we are not exposed to any significant credit risk on cash. </p>
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
588 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10198437 usd
us-gaap Net Income Loss
NetIncomeLoss
-20689 usd
CY2017Q3 us-gaap Unsecured Debt
UnsecuredDebt
50000 usd
CY2017Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.15 pure
CY2023Q4 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
750 usd
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
6087 usd
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
330 usd
CY2024Q1 fhld Note Payable And Accrued Interest
NotePayableAndAccruedInterest
132437 usd
CY2023Q3 fhld Note Payable And Accrued Interest
NotePayableAndAccruedInterest
126680 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
240000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
241297 usd
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56308825 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55308825 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001386044
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-54853
dei Entity Registrant Name
EntityRegistrantName
FREEDOM HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
56-2560951
dei Entity Address Address Line1
EntityAddressAddressLine1
10524 Independence Ave
dei Entity Address City Or Town
EntityAddressCityOrTown
Chatsworth
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91311
dei City Area Code
CityAreaCode
818
dei Local Phone Number
LocalPhoneNumber
357-3155
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55308825 shares
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
588 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
21 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
588 usd
CY2024Q1 us-gaap Assets
Assets
21 usd
CY2023Q3 us-gaap Assets
Assets
588 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
47662 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
44500 usd
CY2024Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
6087 usd
CY2023Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
330 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
240000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
241297 usd
CY2024Q1 fhld Due To Related Parties Current And Non Current
DueToRelatedPartiesCurrentAndNonCurrent
11000 usd
CY2023Q3 fhld Due To Related Parties Current And Non Current
DueToRelatedPartiesCurrentAndNonCurrent
0 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
304749 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
286127 usd
CY2024Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
126350 usd
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
126350 usd
CY2024Q1 us-gaap Liabilities
Liabilities
431099 usd
CY2023Q3 us-gaap Liabilities
Liabilities
412477 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56308825 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55308825 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
5631 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
5531 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9767228 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9765828 usd
CY2024Q1 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
5500 usd
CY2023Q3 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
5500 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10198437 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10177748 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-431078 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-411889 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
588 usd
CY2024Q1 us-gaap Revenues
Revenues
0 usd
CY2023Q1 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q1 us-gaap Professional Fees
ProfessionalFees
14500 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
27770 usd
us-gaap Professional Fees
ProfessionalFees
14795 usd
us-gaap Professional Fees
ProfessionalFees
28048 usd
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
72 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
778 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
137 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2635 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
14572 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
28548 usd
us-gaap Operating Expenses
OperatingExpenses
14932 usd
us-gaap Operating Expenses
OperatingExpenses
30683 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14572 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-28548 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14932 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-30683 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
2863 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
2946 usd
us-gaap Interest Expense
InterestExpense
5757 usd
us-gaap Interest Expense
InterestExpense
6010 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-17435 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-31494 usd
us-gaap Net Income Loss
NetIncomeLoss
-20689 usd
us-gaap Net Income Loss
NetIncomeLoss
-36693 usd
CY2024Q1 fhld Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.00
CY2023Q1 fhld Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.00
fhld Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.00
fhld Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.00
CY2024Q1 fhld Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
55979155 shares
CY2023Q1 fhld Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
34197714 shares
fhld Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
55642158 shares
fhld Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
21616517 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-412471 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-5199 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-417670 usd
CY2023Q1 fhld Issued Stock For Acquisition Of Medcann Amount
IssuedStockForAcquisitionOfMedcannAmount
30000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-31494 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-419164 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-411889 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-3254 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-415143 usd
CY2024Q1 fhld Sold Common Stock Amount
SoldCommonStockAmount
-1500 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-17435 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-431078 usd
us-gaap Profit Loss
ProfitLoss
-20689 usd
us-gaap Profit Loss
ProfitLoss
-36693 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
1865 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
12569 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5757 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
366 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13067 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23758 usd
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
0 usd
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-3358 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
11000 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
4325 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30000 usd
us-gaap Proceeds From Sale Of Longterm Investments
ProceedsFromSaleOfLongtermInvestments
1500 usd
us-gaap Proceeds From Sale Of Longterm Investments
ProceedsFromSaleOfLongtermInvestments
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12500 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30967 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-567 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7209 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
588 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
177 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7386 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
6010 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd

Files In Submission

Name View Source Status
0001477932-24-002996-index-headers.html Edgar Link pending
0001477932-24-002996-index.html Edgar Link pending
0001477932-24-002996.txt Edgar Link pending
0001477932-24-002996-xbrl.zip Edgar Link pending
fhld-20240331.xsd Edgar Link pending
fhld_10q.htm Edgar Link pending
fhld_ex311.htm Edgar Link pending
fhld_ex312.htm Edgar Link pending
fhld_ex321.htm Edgar Link pending
fhld_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
fhld-20240331_def.xml Edgar Link unprocessable
fhld-20240331_pre.xml Edgar Link unprocessable
fhld_10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
fhld-20240331_lab.xml Edgar Link unprocessable
fhld-20240331_cal.xml Edgar Link unprocessable